The domestic vaccine market will rise, whose family will the next heavyweight variety spend?

As the largest vaccine industry country in the world, China's vaccine industry has made great achievements in development, but it is not a strong country in terms of output value and industrial technology Some "heavyweight varieties" of vaccines in the international market have not yet been localized in China, but domestic enterprises are striving to catch up Since Edward chenner first found smallpox vaccine in 1796, it has been more than two hundred years since the development of vaccine The emergence of vaccine has made a variety of infectious diseases in the history of human being preventable and controllable The development of vaccine mainly experienced four stages: the first stage: 1796 - vaccine germination stage, Edward chenner discovered vaccinia vaccine, and started the era of vaccine science; the second stage: 1870-1960 - "conventional vaccine stage" ”Vaccine research and development mainly deal with pathogens through artificial variation, physical and chemical methods to reduce or lose toxicity, but retain immunogenicity, mainly including live attenuated vaccine and inactivated vaccine The third stage: 1960-1990 - "the golden age of vaccine development", is the sub unit vaccine with only antigen components, the combined vaccine for preventing multiple diseases at the same time, the bacterial polysaccharide combined vaccine that can produce immunity to infants and young children, and the birth of synthetic vaccine The toxicity of the vaccine is weakened and the immune effect is further enhanced The fourth stage: from 1990 to now - "new technology stage" With the development of molecular biology and immune science, the emergence of genetic engineering vaccine and DNA vaccine, the upgrading of traditional vaccine, the emergence of new rotavirus vaccine and HPV vaccine, vaccine treatment has begun to expand to the field of non infectious diseases After years of development, at present, from the perspective of technology trend, multi price combination and combined vaccine are the main line; from the perspective of product trend, specialized vaccines such as pneumonia and HPV are the current market focus Typical representatives include Pfizer 13 pneumococcal conjugate vaccine Peier, mesardon HPV vaccine jiadaxiu, Sanofi diphtheria Hib polio conjugate vaccine, and the four price influenza vaccine, which have entered the ranks of "heavy bomb drugs" Although the domestic vaccine market is relatively backward in the field of polyvalent and polysaccharide combined vaccines, there are many enterprises that have broken the situation at present This paper summarizes the application of these international heavyweight domestic enterprises Polyvalent pneumococcal conjugate vaccine Pfizer pneumococcal conjugate vaccine is the main product in the global vaccine market, with global sales of 5.7 billion US dollars in 2016 In November 2016, Peier 13 was listed in China At present, many enterprises in China have applied for the pneumococcal conjugate vaccine, including Beijing minhai, Watson biology, Kexing biological products, Chengdu antjin, Zhifei green bamboo, etc according to the platform of clinical trial publicity, the 13 valent pneumococcal conjugate vaccine of Beijing minhai and Watson biology is currently in phase III clinical, which is expected to be the top Table: Declaration of domestic enterprises of polyvalent pneumococcal conjugate vaccine HPV (human papillomavirus) vaccine in the world, there are four valent and nine valent vaccines Gardasil of mosadon and Cervarix of GSK, which were approved by FDA in 2006, 2014 and 2007 respectively In the U.S market, GSK Cervarix has announced its exit from the U.S market in October 2016 due to "low market demand" The main reason is that MSD jiadaxiu vaccine is on sale In 2016, the global sales of jiadaxiu reached US $2.173 billion In the domestic market, gsk-2 HPV vaccine and msd-4 HPV vaccine were launched in July 2016 and may 2017 respectively, about 10 years later than those in foreign markets Because of the huge market prospect of HPV vaccine, many domestic enterprises have already made arrangements for it Among them, the progress of 2-valent HPV vaccine and 2-valent HPV vaccine of Shanghai Zerun biological Co., Ltd is the fastest, and it has reached phase III clinical stage Table: Declaration of domestic enterprises of HPV preventive vaccine: dtap-hib, dtap-hepb-hib, dtap-hib-mena/c, dtap-ipv quadruple, dtap-hepb-ipv quintuple, dtap-ipv-hib quintuple and dtap-hepb-ipv-hib quintuple In China, due to the restriction of IPV vaccine, there is no declaration of IPV DTaP combined vaccine With the successive listing of two domestic IPV vaccines, China is expected to achieve a breakthrough in the registration and application of IPV DTaP series of joint vaccines in the future At present, Beijing minhai biological DTaP Hib quadruple vaccine has been listed on the market in China In addition, Watson and Wuhan biological products research institute have declared it In addition, DTaP HepB Hib quadruple vaccine, DTaP Hib MENA / C and DTaP HepB vaccine have declared it respectively These varieties are in the issued state, but no relevant clinical trial record has been found on the platform of clinical trial company Table: Declaration of domestic enterprises of DPT combined vaccine